IMPACT ON DAILY PRACTICE | Proceedings of EuroPCR

Will this trial change my practice? PRAMI - treatment of bystander coronary lesions in patients undergoing primary PCI for acute STEMI

EuroIntervention 2014;10:411-412. DOI: 10.4244/EIJV10I3A70

Gabor G. Toth1, MD; Petr Kala2, MD; Alexandra Lansky3, MD; Andreas Baumbach4, MD

1. Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; 2. Masaryk University and University Hospital Brno, Brno, Czech Republic; 3. McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada;

The PRAMI trial, published in the New England Journal of Medicine, investigated in a multicentric randomised fashion whether “on the spot full revascularisation” provides outcome benefits in patients with multivessel disease presenting with a ST-elevation myocardial infarction (STEMI), as compared to a “culprit alone strategy”1. The study enrolled 465 patients with acute STEMI, who underwent primary PCI of the culprit lesion and were randomly assigned 1:1 either to “preventive PCI” of all non-culprit lesions with more than 50% diameter stenosis during the same procedure (234 patients) or to “no preventive PCI” (231 patients).

The study was terminated early on the advice of the data ...

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Share on Facebook Share on Twitter Share on Linkedin